Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Is severe deficiency of ADAMTS-13 specific for thrombotic thrombocytopenic purpura? Yes.

× No keyword cloud information.

11 in total

1. Multiple domains of ADAMTS13 are targeted by autoantibodies against ADAMTS13 in patients with acquired idiopathic thrombotic thrombocytopenic purpura.

Authors: X Long Zheng; Haifeng M Wu; Dezhi Shang; Erica Falls; Christopher G Skipwith; Spero R Cataland; Charles L Bennett; Hau C Kwaan
Journal: Haematologica Date: 2010-04-07 Impact factor: 9.941

2. Shear-Induced Unfolding and Enzymatic Cleavage of Full-Length VWF Multimers.

Authors: Svenja Lippok; Matthias Radtke; Tobias Obser; Lars Kleemeier; Reinhard Schneppenheim; Ulrich Budde; Roland R Netz; Joachim O Rädler
Journal: Biophys J Date: 2016-02-02 Impact factor: 4.033

3. Inhibitory autoantibodies against ADAMTS-13 in patients with thrombotic thrombocytopenic purpura bind ADAMTS-13 protease and may accelerate its clearance in vivo.

Authors: S G Shelat; P Smith; J Ai; X L Zheng
Journal: J Thromb Haemost Date: 2006-08 Impact factor: 5.824

Review 4. Advantages and limits of ADAMTS13 testing in thrombotic thrombocytopenic purpura.

Authors: Massimo Franchini; Pier Mannuccio Mannucci
Journal: Blood Transfus Date: 2008-07 Impact factor: 3.443

Review 5. Molecular basis of ADAMTS13 dysfunction in thrombotic thrombocytopenic purpura.

Authors: Minola Manea; Diana Karpman
Journal: Pediatr Nephrol Date: 2008-09-20 Impact factor: 3.714

6. Novel recombinant glycosylphosphatidylinositol (GPI)-anchored ADAMTS13 and variants for assessment of anti-ADAMTS13 autoantibodies in patients with thrombotic thrombocytopenic purpura.

Authors: D Li; J Xiao; M Paessler; X L Zheng
Journal: Thromb Haemost Date: 2011-09-08 Impact factor: 5.249

Is severe deficiency of ADAMTS-13 specific for thrombotic thrombocytopenic purpura? Yes.

1. Multiple domains of ADAMTS13 are targeted by autoantibodies against ADAMTS13 in patients with acquired idiopathic thrombotic thrombocytopenic purpura.

2. Shear-Induced Unfolding and Enzymatic Cleavage of Full-Length VWF Multimers.

3. Inhibitory autoantibodies against ADAMTS-13 in patients with thrombotic thrombocytopenic purpura bind ADAMTS-13 protease and may accelerate its clearance in vivo.

Review 4. Advantages and limits of ADAMTS13 testing in thrombotic thrombocytopenic purpura.

Review 5. Molecular basis of ADAMTS13 dysfunction in thrombotic thrombocytopenic purpura.

6. Novel recombinant glycosylphosphatidylinositol (GPI)-anchored ADAMTS13 and variants for assessment of anti-ADAMTS13 autoantibodies in patients with thrombotic thrombocytopenic purpura.

Review 7. Molecular biology of ADAMTS13 and diagnostic utility of ADAMTS13 proteolytic activity and inhibitor assays.

Review 8. Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura.

Review 9. STEC-HUS, atypical HUS and TTP are all diseases of complement activation.

Review 10. Thrombotic microangiopathy in haematopoietic stem cell transplantation: diagnosis and treatment.